Us Fda Committee Votes Against Approval Of Acadia Pharma Pimavanserin To Treat Alzheimers Disease Psychosis

Acadia Pharmaceuticals Inc., A Company Advancing Breakthroughs In Neuroscience To Elevate Life, Announced The Outcome Of The Us Food And Drug Administration (Fda) Psychopharmacologic Drugs Advisory Committee (Pdac) Meeting For Pimavanserin For The Treatment Of Hallucinations And Delusions Associated With Alzheimer